AbbVie to buy neuroscience drugmaker Cerevel Therapeutics for $8.7bn
The proposed acquisition will include Cerevel’s clinical-stage pipeline of assets focused on psychiatric and neurological disorders, which will…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
07 Dec 23
The proposed acquisition will include Cerevel’s clinical-stage pipeline of assets focused on psychiatric and neurological disorders, which will…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
05 Dec 23
Through the acquisition, Roche will get access to Carmot’s portfolio of incretins, including its lead asset CT-388, along…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Dec 23
Jaypirca (pirtobrutinib) 100mg or 50mg tablets taken as a once-daily 200 mg dose, is indicated for the treatment…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Dec 23
The topline data showed statistically significant change in body weight from baseline with danuglipron administration with changes at…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
01 Dec 23
Through the acquisition of ImmunoGen for a total equity value of around $10.1bn, AbbVie is enabled to advance…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
28 Nov 23
ARCT-032 has been designed to use the firm’s LUNAR lipid-mediated aerosolised platform to provide CFTR messenger RNA to…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
27 Nov 23
Nefecon is a patented, oral delayed-release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 Nov 23
EP0031 is a potential next-generation selective RET inhibitor with a wide activity against general RET fusions and mutations,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Nov 23
Under the agreement, Merck will acquire all the outstanding shares of Massachusetts-based Caraway with earnout milestones related to…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Nov 23
Under the partnership, both the firms will jointly develop and produce NK cells and help in the development…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates